Clinical Trial

The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer

Study acronym: RAISE
Completed
View on ClinicalTrials.gov →
Summary
This study was a multicenter, real-world observational study aimed at characterizing the genomic landscape of recurrence in patients with EGFR-sensitizing mutation-positive early-stage (clinical stage IB-IIIA) non-small cell lung cancer who received adjuvant osimertinib after surgery.
Protocol Amendment History 2 changes
critical Trial completed 2026-07-22
notable Enrollment reduced: 60 -> 43 participants 2026-07-22
Trial Details
NCT Number NCT06477055
Lead Sponsor Hunan Province Tumor Hospital
Conditions Non-small Cell Lung Cancer
Enrollment 43 participants
Start Date 2025-12-02
Primary Completion 2026-04-21 (estimated)
Study Completion 2026-04-21 (estimated)
Updated on ClinicalTrials.gov 2026-07-21